Literature DB >> 9216835

Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.

P L Beaulieu1, D Wernic, A Abraham, P C Anderson, T Bogri, Y Bousquet, G Croteau, I Guse, D Lamarre, F Liard, W Paris, D Thibeault, S Pav, L Tong.   

Abstract

A series of HIV protease inhibitors containing a novel (hydroxyethyl)amidosuccinoyl core has been synthesized. These peptidomimetic structures inhibit viral protease activity at low nanomolar concentrations (IC50 < 10 nM for HIV-1 protease). The inhibition constant (Ki) for inhibitor 19 was determined to be 7.5 pM against HIV-1 and 1.2 nM against HIV-2 proteases, respectively. Several compounds (19-24) inhibited HIV-1 replication in cell culture assays with 50% effective concentrations (EC50) = 3.7-35 nM. This series of inhibitors was found to exhibit poor bioavailability (< 10%) in the rat, following oral administration. The synthesis and biological properties of these compounds are discussed. In addition, an X-ray structure of one of these inhibitors (23) in complex with HIV-2 protease provides insight into the binding mode of this novel class of HIV protease inhibitors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9216835     DOI: 10.1021/jm9606608

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Impact of antiretroviral protocols on dynamics of AIDS progression markers.

Authors:  S Resino; J M Bellón; S Sánchez-Ramón; D Gurbindo; J Ruiz-Contreras; J A León; J T Ramos; M A Muñóz-Fernández
Journal:  Arch Dis Child       Date:  2002-02       Impact factor: 3.791

2.  Structural Insights to Human Immunodeficiency Virus (HIV-1) Targets and Their Inhibition.

Authors:  Murugesan Vanangamudi; Pramod C Nair; S E Maida Engels; Senthilkumar Palaniappan; Vigneshwaran Namasivayam
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.